ClinicalTrials.gg

Hodgkin Disease clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,384 studies for Hodgkin Disease across more than 10 countries. 163 are recruiting or about to start. 586 of them are mainly about Hodgkin Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 7,175 studies for Hodgkin Disease. How that becomes 1,384 here

This page counts the studies the registry files under Hodgkin Disease, and those it files under no condition that list Hodgkin Diseasethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 17, 2026. How condition pages count

  1. 7,175Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −71List Hodgkin Disease as a condition, but the registry did not file them under itMost often written as “Classical Hodgkin Lymphoma” (18), “Recurrent/Refractory Childhood Hodgkin Lymphoma” (14), and “Classic Hodgkin Lymphoma” (6). The registry filed them under other conditions only, most often Recurrence (26) and Lymphoma, Large B-Cell, Diffuse (18).
  3. −5,723Match it another way29 name it in the title, 46 in a keyword, and 5,648 by a synonym or other text the search reads.
  4. 1,381Counted here and found by its search79 of them list Hodgkin Disease in their own words; the registry filed them under no condition.
  5. +3
    Counted here, but its search does not find them
  6. 1,384The count on this page

Status

Completed
804
Terminated
178
Recruiting
136
Status unknown
99
Active, not recruiting
88
Withdrawn
45

Phase

Phase 2
636
Phase 1
447
Phase 3
113
Early Phase 1
13
Phase 4
9

Where

United States
970
Italy
98
Germany
75
France
72
Canada
61
China
57

Who develops what

Add Hodgkin Disease to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 5 companies, 3 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Dr. Reddy's Laboratories, Takeda and Jecho Biopharmaceuticals here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
bendamustineRecent, limited
Evidence
  • NCT05508867 · Merck & Co., Inc · Phase 2 · comparator · “bendamustine” · registered Aug 2022
  • NCT04268706 · Tessa Therapeutics · Phase 2 · live · background · “Bendamustine” · registered Feb 2020
  • NCT02733042 · Bristol-Myers Squibb · Phase 2 · background · “Bendamustine” · registered Apr 2016
  • NCT01716806 · Pfizer · Phase 2 · background · “bendamustine” · registered Oct 2012
Teva Pharmaceutical Industries, Ltd.25% of its industry studiesUS: off-patent, 3 generics marketed11 study
CyclophosphamideRecent, limited
Evidence
  • NCT05883449 · Affimed GmbH · Phase 2 · background · “Cyclophosphamide” · registered May 2023
  • NCT03407144 · Merck & Co., Inc · Phase 2 · live · background · “cyclophosphamide” · registered Jan 2018
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed11 study
fludarabineRecent, limitedPhase 4 trial recorded
Evidence
  • NCT05883449 · Affimed GmbH · Phase 2 · background · “Fludarabine” · registered May 2023
  • NCT04268706 · Tessa Therapeutics · Phase 2 · live · background · “Fludarabine” · registered Feb 2020
Beijing Biotech18% of its industry studies11 study

11 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Mar 2027 est.Carmustine with Propylene Glycol Formulation VI-0609 · VIVUS LLC · Phase 2 named, not the main aimvs CarmustineNCT06915246 A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma — primary endpoint: Evaluation of infusion-related toxicities · 49 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Hodgkin Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 28 open · Alkylating agents 18 open · Antimetabolites 12 open · Antibody-drug conjugates (ADCs) 9 open · Antimitotic agents 6 open

Coming up

74studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 136 Hodgkin Disease studies recruiting now, 73 (54%) set no upper age limit and 51 (38%) stop at 75 or younger. 46 (34%) take children under 18. 2 (1%) are for women only and 1 (1%) for men only; 10 (7%) take healthy volunteers.

Recruiting studies that take each age, of 136
AgeWomenMen
1030 (22%)30 (22%)
18131 (96%)130 (96%)
30120 (88%)119 (88%)
40113 (83%)113 (83%)
50114 (84%)113 (83%)
65108 (79%)107 (79%)
75101 (74%)100 (74%)
8580 (59%)79 (58%)

Across all 1,384 studies, recruiting or not: 39% stop at 75 or younger and 22% at 65; 34% take children; 1% are for women only and <1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hodgkin Disease studies take

Of 205 phase 2 interventional studies under Hodgkin Disease, half reached primary completion within 75 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 157 mo41–79 · 91 studies—60 mo41–80 · 66 studies
Phase 1/269 mo53–97 · 63 studies—72 mo59–103 · 48 studies
Phase 275 mo42–111 · 205 studies—80 mo48–115 · 182 studies
Phase 375 mo52–108 · 33 studies—81 mo51–108 · 27 studies
Interventional, no phase43 mo29–128 · 53 studies—43 mo29–128 · 50 studies
Observational61 mo34–149 · 66 studies—63 mo31–149 · 59 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,384. Browse all 1,384 → or search them.